Clinical beta
FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.
Drug Monograph
Moxifloxacin
Fluoroquinolone (PO, IV)
Indication
CAP β’ complicated IAI selected β’ SSTI selected β’ TB MDR sometimes
INDICATIONS (CORE USE)
Broader **anaerobe** coverage vs levoflox β **QT** liability; **hepatotoxicity** signal; **no renal adjustment** (hepatic elimination) β **do not use for UTI** (urine penetration inadequate).
ADULT DOSE (STANDARD)
400 mg PO/IV daily
MAX DOSE
400 mg/day
Route
PO, IV
PEDIATRIC DOSE
Not routine
Must-not-miss safety points
Major warning
- **QT prolongation** β stronger than some FQ - **Hepatotoxicity** β LFTs if prolonged; EU restrictions historically - **Not for uncomplicated UTI** β fails urine levels - Same tendon / CNS / aneurysm class warnings
USE IF: CAP, some intra-abd/SSTI when anaerobe box needed and beta-lactam allergy pathway (guideline). AVOID IF: Urinary source infection; baseline long QT; need renal dose adjustment for renal failure (drug accumulates differently β check hepatic+renal combined illness).
Primary
Secondary
Other
STANDARD (ADULT PO)
400 mg IV/PO daily
ADULT DOSE
400 mg daily; no CrCl-based reduction for renal alone β **severe hepatic impairment** contraindicated IV per label
PEDIATRIC DOSE
Avoid.
MAX DOSE
400 mg/day
Practical Note
Oral bioavailability good β IVβPO early.
Clinical warnings
Adverse effects
Pediatrics
Not routine
Pregnancy
Avoid pregnancy
Lactation
caution.
Renal impairment
No dose change renal alone β **avoid substituting moxi for levoflox in CKD without understanding this** **CrCl scaffold (FMBM β titrate to FDA/SFDA label + institutional pharmacy nomogram):** - **CrCl β₯50** β standard (agent-specific) - **CrCl 10β50** β extend interval or β dose (**moxifloxacin:** often minimal CrCl change β hepatic clearance) - **CrCl <10** β label tables (cipro/levo often q24β48h); **seizure/QT risk** if accumulated; **HD:** consult pharmacy
Hepatic impairment
Severe hepatic impairment β IV contraindicated; PO caution per label.
Elderly
QT + fall risk.
IV infusion per product; PO with or without food.
Clinical Picture
**Life-threatening (first):** **seizures**; **torsades** (QT); **suicidal ideation** with agitation. **Secondary:** tendinopathy; GI symptoms.
Immediate Actions
Stop FQ β seizure precautions; ECG; correct electrolytes; glucose check if altered MS
Antidote
No specific antidote; treat complications (e.g. anaphylaxis β epinephrine per ACLS)
Decontamination
Recent PO overdose β charcoal if early
Escalation
Seizures, torsades, severe agitation β **ICU** / psychiatry; **severe toxicity with renal failure β consider hemodialysis** (limited for many FQs but case-by-case + supportive AKI) β nephrology + pharmacy
Common mistakes, resistance logic, and bedside traps
**Anaerobe-augmented FQ** with **big QT** and **hepatic metabolism**. **Not for UTI**. Renal failure β automatic dose cut β different drug.
Compare to beta-lactam + metronidazole for anaerobes often safer from QT perspective. Stewardship: reserve for true beta-lactam allergy serious infection pathways. *Stewardship (all antimicrobials):* Empiric choice β syndrome severity + **local antibiogram**; shortest effective course.
Hepatic elimination dominant; long half-life daily dosing.
Fluoroquinolone with improved anaerobe vs levofloxacin.
Global data (no country-specific data available)
Saudi Arabia
(placeholder β verify local formulary)
Common trade names are curated examples only β formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.
Saudi Arabia
International